Search results

716 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
NICE Pathways Remove NICE Pathways filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Endo-SPONGE for treating low rectal anastomotic leakage (MT461)

In development [GID-MT539] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Peezy Midstream for urine collection (MT446)

In development [GID-MT538] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Type

Medical technologies guidance

Status

In development
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)

In development [GID-MT550] Expected publication date: 04 October 2021

Type

Medical technologies guidance

Status

In development
3C Patch System for treating diabetic foot ulcers (MT539)

In development [GID-MT559] Expected publication date: 19 January 2022

Type

Medical technologies guidance

Status

In development
Leukomed Sorbact for preventing surgical site infection (MT496)

In development [GID-MT541] Expected publication date: 03 February 2021

Type

Medical technologies guidance

Status

In development
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)

In development [GID-MT548] Expected publication date: 04 May 2021

Type

Medical technologies guidance

Status

In development
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Sleepio for adults with difficulty sleeping (MT443)

In development [GID-MT552] Expected publication date: 03 August 2021

Type

Medical technologies guidance

Status

In development
Prontosan for acute and chronic wounds

In development [GID-MT551] Expected publication date: 05 October 2021

Type

Medical technologies guidance

Status

In development
Synergo for non-muscle-invasive bladder cancer

In development [GID-MT553] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Danis Stent for acute oesophageal variceal bleeds (MT450)

In development [GID-MT537] Expected publication date: 25 May 2021

Type

Medical technologies guidance

Status

In development
Alpha Stim AID (MT477)

In development [GID-MT542] Expected publication date: 08 March 2021

Type

Medical technologies guidance

Status

In development
MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care

In development [GID-MT556] Expected publication date: 23 February 2022

Type

Medical technologies guidance

Status

In development
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation

In development [GID-MT554] Expected publication date: 06 January 2022

Type

Medical technologies guidance

Status

In development
MT507 Plus Sutures for preventing surgical site infection (MIB204)

In development [GID-MT558] Expected publication date: 09 November 2021

Type

Medical technologies guidance

Status

In development
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

In development [GID-MT557] Expected publication date: 22 March 2022

Type

Medical technologies guidance

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]

Proposed [GID-TA10736] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

Proposed [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

Proposed [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]

Proposed [GID-TA10632] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

Proposed [GID-TA10662] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

Proposed [GID-TA10707] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

Proposed [GID-TA10709] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Proposed [GID-TA10748] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

Proposed [GID-TA10750] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]

Proposed [GID-TA10751] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Proposed [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Melphalan flufenamide for Multiple myeloma in Relapsing or refractory In combination with dexamethasone [ID3862]

Proposed [GID-TA10744] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Proposed [GID-TA10745] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed